总投资4.75亿美元 阿斯利康无锡小分子药物新工厂正式开工

Core Viewpoint - AstraZeneca has officially opened a new small molecule drug manufacturing facility in Wuxi, China, with a total investment of $475 million, marking a significant expansion of its supply chain in the region [1] Group 1: Investment and Infrastructure - The new facility covers an area of approximately 30,000 square meters and will be equipped with two advanced tablet continuous manufacturing process systems and seven sustainable pharmaceutical packaging production lines [1] - The facility is primarily focused on the production of innovative cardiovascular drugs from AstraZeneca's research pipeline, with production expected to commence in the fourth quarter of 2028 [1] Group 2: Strategic Expansion - This development follows the completion of the main structure of the first phase of the inhalation aerosol production supply base in Qingdao, indicating AstraZeneca's ongoing commitment to deepening its supply chain presence in China [1]